Medications for Pulmonary Arterial Hypertension: A Review
Author Information
Author(s): Li Qiang, Kuang Hongyu, Yi Qijian, Du Huaan
Primary Institution: Children's Hospital of Chongqing Medical University, Chongqing, China
Hypothesis
To evaluate the clinical efficacy and safety of targeted drugs in patients with pulmonary arterial hypertension (PAH) with cardiac function grades III–IV.
Conclusion
Monotherapy with targeted drugs is safe and effective for patients with PAH and cardiac function grades III-IV.
Supporting Evidence
- Monotherapy with bosentan improved 6MWD by ~53.67 m.
- Prostacyclin analogs increased 6MWD by approximately 25.02 meters.
- Combination therapy improved cardiac function in ~59.1% of patients.
Takeaway
This study looked at how well certain medicines work for kids with a serious lung problem. It found that some medicines help them walk better and feel better without making them sick.
Methodology
The study involved a systematic review and meta-analysis of randomized controlled trials, analyzing data from PubMed, EMBASE, and Cochrane Library.
Potential Biases
No significant publication bias was detected among the studies.
Limitations
The study primarily focused on short-term effects and may not reflect long-term outcomes.
Participant Demographics
Patients with pulmonary arterial hypertension classified as functional class III-IV.
Statistical Information
P-Value
p < 0.0001
Confidence Interval
[43.57, 63.77] meters
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website